Main menu button

News

Analysis Biovica: Positive results in run-up to FDA process
25 mar 2019
Analysis Biovica: Positive results in run-up to FDA process
Equity Research
Analysis Follicum: Progress with new formulation
25 mar 2019
Analysis Follicum: Progress with new formulation
Equity Research
Analysis, Cantargia: Second half in CANFOUR study
25 mar 2019
Analysis, Cantargia: Second half in CANFOUR study
Equity Research
Analysis, Svenska Aerogel: New capital for growth phase
21 mar 2019
Analysis, Svenska Aerogel: New capital for growth phase
Equity Research
Analysis, New Wave Group: Strong brand presence
21 mar 2019
Analysis, New Wave Group: Strong brand presence
Equity Research
Analysis Amasten: New production of residential units adds value
20 mar 2019
Analysis Amasten: New production of residential units adds value
Equity Research
Analysis, FRISQ: According to plan
18 mar 2019
Analysis, FRISQ: According to plan
Equity Research
Analysis Absolicon: Upside from here!?
15 mar 2019
Analysis Absolicon: Upside from here!?
Equity Research
Analysis; AdderaCare: Focus on profitability
14 mar 2019
Analysis; AdderaCare: Focus on profitability
Equity Research
12 mar 2019
Equity Research
12 mar 2019
Equity Research
Analysis, Combigene: Improved financial position
12 mar 2019
Analysis, Combigene: Improved financial position
Equity Research
Analysis Flowscape: Approaching break-even with significant potential
08 mar 2019
Analysis Flowscape: Approaching break-even with significant potential
Equity Research
Analysis, Kopy Goldfields: Higher gold a timely boon?
08 mar 2019
Analysis, Kopy Goldfields: Higher gold a timely boon?
Equity Research
Analysis Kungsleden: Delivers on its strategy
06 mar 2019
Analysis Kungsleden: Delivers on its strategy
Equity Research
Analysis Fastator: NAV still growing
06 mar 2019
Analysis Fastator: NAV still growing
Equity Research
Analysis SolTech: Acquisitions create upside in the share
05 mar 2019
Analysis SolTech: Acquisitions create upside in the share
Equity Research
Analysis Consilium: Improved outlook for 2019
04 mar 2019
Analysis Consilium: Improved outlook for 2019
Equity Research
Analysis, Bonesupport: CERTiF(y)ied for growth
01 mar 2019
Analysis, Bonesupport: CERTiF(y)ied for growth
Equity Research
Analysis, Coor: Continued long term potential
01 mar 2019
Analysis, Coor: Continued long term potential
Equity Research